cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Curis Inc
50 own
49 watching
Current Price
$3.22
$-0.12
(-3.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
35.1M
52-Week High
52-Week High
17.49000
52-Week Low
52-Week Low
2.86000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization35.1M
icon52-Week High17.49000
icon52-Week Low2.86000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Curis Inc do?
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Read More
How much money does Curis Inc make?
News & Events about Curis Inc.
PR Newswire
1 year ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., May 5, 2023 LEXINGTON, Mass., May 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
1 year ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., April 5, 2023 LEXINGTON, Mass., April 5, 2023 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
1 year ago
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call PR Newswire LEXINGTON, Mass., March 8, 2023 LEXINGTON, Mass., March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused...
Benzinga
1 year ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Curis Inc share price today?
plus_minus_icon
Can Indians buy Curis Inc shares?
plus_minus_icon
How can I buy Curis Inc shares from India?
plus_minus_icon
Can Fractional shares of Curis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Curis Inc stocks?
plus_minus_icon
What is today’s traded volume of Curis Inc?
plus_minus_icon
What is today’s market capitalisation of Curis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Curis Inc?
plus_minus_icon
What percentage is Curis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Curis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.22
$-0.12
(-3.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00